EUVIMEDEUVIMED entdecken
Crossref

Role of [ 18 F]F-Fluciclovine PET/CT in Patients with Biochemical Recurrence of Prostate Cancer and Negative PSMA PET Results: A Single-Center Study

Laszlo Szidonya, Sebastian Obrzut, Jeong Y Lim, Emile Latour, Gagandeep Choudhary, Arthur Hung, Nadine Mallak

Journal of Nuclear Medicine · 29.10.2026 · jnumed.126.272834

DOI: 10.2967/jnumed.126.272834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 29.10.2026. Verfasst von Laszlo Szidonya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Radiology, Oregon Health & Science University, Portland, Oregon. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our purpose was to evaluate whether [18F]F-fluciclovine PET/CT detects sites of disease in patients with biochemical recurrence (BCR) of prostate cancer and negative findings on prostate-specific membrane antigen (PSMA) PET and to assess its impact on intended management. Methods: In this prospective single-arm study (NCT05722925), 50 patients with BCR (prostate-specific antigen [PSA] ≥ 0.2 ng/mL) and negative findings on PSMA PET underwent [18F]F-fluciclovine PET/CT within 30 d of the previous imaging. Detection rate, distribution of disease, PSA-stratified analysis, management impact, and correct localization rate were assessed using descriptive statistics and exact CI. Results: [18F]F-fluciclovine PET had positive findings in 28 of 50 patients (56%; 95% CI, 41%-70%). Disease was confined to the prostate bed in 14 patients (50%), whereas 14 (50%) demonstrated nodal or distant metastases. Detection rate increased with PSA, from 44% at a PSA of 0.2-0.5 ng/mL to 100% at a PSA of 5 ng/mL or higher. The intended management changed in 71% of patients after the [18F]F-fluciclovine PET: 87% of patients with positive findings and 54% with negative findings. Among patients with an available reference standard (n = 14), all positive findings were confirmed to be true-positive. Conclusion: [18F]F-fluciclovine PET detected recurrent disease in over half of patients with negative PSMA PET findings and frequently altered management, supporting its complementary role in selected patients with BCR.

Schlagwörter

Stichwörter der Autor:innen

PSMAbiochemical recurrencefluciclovinemolecular imagingprostate cancer

Autor:innen und Institutionen

  • Department of Diagnostic Radiology, Oregon Health & Science University, Portland, Oregon.
  • Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon; and.
  • Department of Radiation Oncology, Oregon Health & Science University, Portland, Oregon.
  • Department of Diagnostic Radiology, Oregon Health & Science University, Portland, Oregon; mallak@ohsu.edu.

Zitieren

APA

Szidonya, L., Obrzut, S., Lim, J. Y., Latour, E., Choudhary, G., Hung, A., & Mallak, N. (2026). Role of [ 18 F]F-Fluciclovine PET/CT in Patients with Biochemical Recurrence of Prostate Cancer and Negative PSMA PET Results: A Single-Center Study. Journal of Nuclear Medicine, jnumed.126.272834. https://doi.org/10.2967/jnumed.126.272834

Vancouver

Szidonya L, Obrzut S, Lim JY, Latour E, Choudhary G, Hung A, et al. Role of [ 18 F]F-Fluciclovine PET/CT in Patients with Biochemical Recurrence of Prostate Cancer and Negative PSMA PET Results: A Single-Center Study. Journal of Nuclear Medicine. 2026:jnumed.126.272834. doi:10.2967/jnumed.126.272834

BibTeX
@article{Szidonya2026,
  author = {Szidonya, Laszlo and Obrzut, Sebastian and Lim, Jeong Y and Latour, Emile and Choudhary, Gagandeep and Hung, Arthur and Mallak, Nadine},
  title = {Role of [ 18 F]F-Fluciclovine PET/CT in Patients with Biochemical Recurrence of Prostate Cancer and Negative PSMA PET Results: A Single-Center Study},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  pages = {jnumed.126.272834},
  doi = {10.2967/jnumed.126.272834}
}
Kostenlos starten →